Literature DB >> 20614563

Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2010        PMID： 20614563     DOI： 10.1038/nrclinonc.2010.93

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

Authors:  Maurizio Scaltriti; Sarat Chandarlapaty; Ludmila Prudkin; Claudia Aura; José Jimenez; Pier Davide Angelini; Gertrudis Sánchez; Marta Guzman; Josep Lluis Parra; Catherine Ellis; Robert Gagnon; Maria Koehler; Henry Gomez; Charles Geyer; David Cameron; Joaquin Arribas; Neal Rosen; José Baselga
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531
  1 in total
  1 in total

Review 1.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.